Intra-Cellular Therapies Inc. (NASDAQ:ITCI) traded today at a new 12-month high of $56.81. So far today approximately 471,000 shares have been exchanged, as compared to an average 30-day volume of 1.5 million shares.
Over the past year, Intra-Cellular Therapies Inc. has traded in a range of $28.40 to $56.81 and is now at $56.02, 97% above that low.
Potential upside of 0.9% exists for Intra-Cellular Therapies Inc., based on a current level of $56.02 and analysts’ average consensus price target of $56.52.
Intra-Cellular Therapies Inc. is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company’s business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected
About IBN (InvestorBrandNetwork)
IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.
For more information on IBN, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
